All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Apremilast for patients with genital psoriasis: Week 32 results from the phase III DISCREET trial
|
The multicenter, randomized, double-blind, placebo-controlled phase III DISCREET trial (NCT03777436) evaluated the safety and efficacy of apremilast, an oral PDE4 inhibitor, in patients with moderate-to-severe genital psoriasis.1 Patients were randomized 1:1 to receive either apremilast 30 mg twice daily (n = 143) or placebo (n = 146) for 16 weeks.1 At Week 16, all patients (n = 229) entered the apremilast extension phase and received apremilast up to Week 32.1 Week 16 results were previously reported by the PsOPsA Hub. Week 32 results were presented at the EADV 2024 Congress by Joseph Merola.1 |
| Key learnings |
| At Week 32, the modified genital PGA response rates were 40.3% and 51.8% and the overall sPGA rates were 30.3% and 33.6% in patients who received apremilast and placebo/apremilast, respectively. |
| GPI-NRS response rates were 46.5% and 48.4% in patients who received apremilast and placebo/apremilast, respectively. |
| DLQI improved from baseline by −48.6% and −55.9% and DLQI-Q9, focused on sexual function, improved by −58.8% and −57.2% in patients who received apremilast and placebo/apremilast, respectively. |
| The safety outcomes were consistent with the known safety profile of apremilast and similar to the Week 16 analysis. |
| Patients with moderate-to-severe genital psoriasis treated with apremilast had a clinically meaningful reduction in disease severity, signs, and symptoms, and improved quality of life, regardless of apremilast or placebo treatment in the first 16 weeks. |
Abbreviations: DLQI, Dermatology Life Quality Index; DLQI-Q9, DLQI question 9; EADV, European Academy of Dermatology and Venereology; GPI-NRS, Genital Psoriasis Itch Numeric Rating Scale; PDE4, phosphodiesterase 4; PGA, Physician’s Global Assessment; QoL, quality of life; sPGA, static PGA.
- Merola J. Apremilast in patients with moderate to severe genital psoriasis: Week 32 results from the phase 3 DISCREET study. Oral Abstract #FC06.05. Presented at: European Academy of Dermatology and Venereology Congress; Sep 25–28, 2024; Amsterdam, NL.
More about...
Your opinion matters
10 votes - 49 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox